Connect Biopharma (NASDAQ:CNTB) Chief Executive Officer Barry Quart said the company's rademikibart program continues to show a differentiated clinical and mechanistic profile as the company awaits ...

Alumis is exploring strategic alternatives for its would-be rival to Amgen’s Tepezza, choosing to punt the program rather ...

India’s new 7-minute lung cancer immunotherapy injection may improve treatment convenience, survival outcomes, and patient ...

Novo Nordisk and Biogen are underpriced and stand to gain from new indications for their blockbuster therapies.

(NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization to expand the approved indication for HYMPAVZI ® (marstacimab) to include patients 12 years of age and ...

Patients were safely able to return home and receive the diuretic by minipump, minimizing their time spent at the hospital.

A major amendment has prompted the FDA to extend its review of subcutaneous lecanemab as a starting dose for early Alzheimer disease.

US Net Revenue Guidance -- Full-year 2025 guidance raised from $525 million to $560 million, with Q2 targeted at $135 million. New Patient Enrollment -- Highest level since launch achieved in the ...

Please provide your email address to receive an email when new articles are posted on . In addition to headache, pyrexia and urticaria, reported adverse events included vomiting, nausea and ...

Subcutaneous opioid delivery maintained comparable pain management efficacy to intravenous administration and decreased use of antiemetics, to support more patient-centered practices. Implementation ...